Molecular Testing in Early Diagnosis and Clinical Assessment of Alzheimer’s Disease: A Narrative Review
Open Access
- 6 March 2026
- journal article
- review article
- Published by MDPI AG in Applied Sciences
- Vol. 16 (5) , 2554
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and one of the leading causes of dementia worldwide. With the increasing prevalence driven by population aging, there is a growing demand for early, accurate, and biologically grounded diagnostic approaches. Advances in molecular diagnostics have created new opportunities for early disease detection, staging, and monitoring of therapeutic responses, reshaping contemporary diagnostic workflows. Validated cerebrospinal fluid biomarkers—amyloid-β, total tau, and phosphorylated tau—form the core of current biologically based diagnostic criteria, while blood-based biomarkers such as plasma p-tau and neurofilament light chain are gaining prominence due to their minimally invasive nature and scalability. Advanced imaging techniques, including amyloid and tau positron emission tomography, further enhance diagnostic accuracy and support differentiation of AD from other neurodegenerative disorders. Despite these advances, the clinical implementation of molecular diagnostics remains limited by methodological heterogeneity, biological variability, and the lack of standardized analytical and clinical frameworks. Addressing these translational challenges is essential for integrating molecular biomarkers into routine clinical practice and for enabling reliable, large-scale screening and early diagnosis of AD.Keywords
This publication has 114 references indexed in Scilit:
- Facets of language performance in early‐onset and late‐onset Alzheimer's disease dementiaAlzheimer's & Dementia, 2025
- MiRNA‐501‐3p and MiRNA‐502‐3p: A promising biomarker panel for Alzheimer's diseaseClinical and Translational Medicine, 2025
- Oxidative stress–mediated neuroinflammation in Alzheimer’s diseaseNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratificationAlzheimer's & Dementia, 2024
- Characterization of the long noncoding RNA transcriptome in human preimplantation embryo developmentJournal of Assisted Reproduction and Genetics, 2023
- Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohortAlzheimer's & Dementia, 2023
- Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement DisordersJAMA Neurology, 2019
- Prevalence of Cerebral Amyloid Pathology in Persons Without DementiaJAMA, 2015
- Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal modelsDiabetes/Metabolism Research and Reviews, 2014